Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.48 USD | +2.78% | -12.73% | -58.62% |
Valuation
Fiscal Period: December | 2019 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 5.174 | 1.164 | 2.928 | - | - |
Enterprise Value (EV) 1 | 3.789 | 1.164 | 2.928 | 2.928 | 2.928 |
P/E ratio | -0.69 x | -0.37 x | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | -7,15,778 x | - | - | - | - |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 8.26 | 398 | 2,240 | - | - |
Reference price 2 | 626.7 | 2.927 | 1.307 | 1.307 | 1.307 |
Announcement Date | 16/04/20 | 10/04/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | -7.228 | - | - | - | - |
EBIT 1 | -7.259 | - | -7.846 | -10.29 | -12.76 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) | -6.826 | - | - | - | - |
Net income | -6.632 | -3.869 | - | - | - |
Net margin | - | - | - | - | - |
EPS | -912.0 | -7.880 | - | - | - |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 16/04/20 | 10/04/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2019 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT | -3.152 | - | - | - | - |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income | -3.028 | - | - | - | - |
Net margin | - | - | - | - | - |
EPS | -248.0 | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 16/04/20 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | 1.38 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex | 3.02 | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 16/04/20 | 10/04/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+5.53% | 11TCr | |
+11.01% | 11TCr | |
-11.88% | 2.23TCr | |
-3.23% | 2.19TCr | |
-5.94% | 1.86TCr | |
-36.52% | 1.81TCr | |
-10.32% | 1.7TCr | |
+3.77% | 1.37TCr | |
+37.65% | 1.24TCr |
- Stock Market
- Equities
- CYTO Stock
- CYTO Stock
- Financials Altamira Therapeutics